Cargando…
Platelet caspase‐1 and Bruton tyrosine kinase activation in patients with COVID‐19 is associated with disease severity and reversed in vitro by ibrutinib
BACKGROUND: Severity of coronavirus disease 2019 (COVID‐19) is often associated with thrombotic complications and cytokine storm leading to intensive are unit (ICU) admission. Platelets are known to be responsible for abnormal hemostasis parameters (thrombocytopenia, raised D‐dimers, and prolonged p...
Autores principales: | Claude, Livia, Martino, Frédéric, Hermand, Patricia, Chahim, Bassel, Roger, Pierre‐Marie, de Bourayne, Marie, Garnier, Yohann, Tressieres, Benoit, Colin, Yves, Le Van Kim, Caroline, Romana, Marc, Baccini, Véronique |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732813/ https://www.ncbi.nlm.nih.gov/pubmed/36514346 http://dx.doi.org/10.1002/rth2.12811 |
Ejemplares similares
-
The Bruton tyrosine kinase inhibitor ibrutinib improves anti-MAG antibody polyneuropathy
por: Castellani, Francesca, et al.
Publicado: (2020) -
The Bruton’s Tyrosine Kinase Inhibitor Ibrutinib Impairs the Vascular Development of Zebrafish Larvae
por: Wang, Kun, et al.
Publicado: (2021) -
Bruton’s Tyrosine Kinase (BTK) Inhibitor (Ibrutinib)-Suppressed Migration and Invasion of Prostate Cancer
por: Zhu, Zhen, et al.
Publicado: (2020) -
Mechanism of covalent binding of ibrutinib to Bruton's tyrosine kinase revealed by QM/MM calculations
por: Voice, Angus T., et al.
Publicado: (2021) -
The dosing of ibrutinib and related Bruton’s tyrosine kinase inhibitors: eliminating the use of brute force
por: Ratain, Mark J., et al.
Publicado: (2022)